Cartesian Therapeutics, Inc. (RNAC)

NGM – Real vaqt narxi. Valyuta: USD

8.70

+0.17 (1.99%)

Yopilishda: May 12, 2026, 4:00 PM EDT

04.05.2026

Cartesian Therapeutics Announces New Employment Inducement Grants

FREDERICK, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to five new employees. On May 1, 2026, the Company issued to these employees options to purchase an aggregate of 317,200 shares of the Company's common stock with an exercise price of $6.22, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The options vest as to 25% on May 1, 2027, and then in thirty-six substantially equal monthly installments thereafter such that the options will be fully vested on May 1, 2030. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company.

30.04.2026

Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates

Cartesian Therapeutics, Inc. (RNAC) came out with a quarterly loss of $1.46 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to a loss of $0.68 per share a year ago.

30.04.2026

Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome initiated Multiple patients enrolled in Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis Approximately $120.4 million cash, cash equivalents and restricted cash as of March 31, 2026 , expected to support planned operations into mid-2027, including completion of ongoing Phase 3 AURORA trial FREDERICK, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“we”, the “Company” or “Cartesian”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today reported financial results for the first quarter ended March 31, 2026, and outlined recent business updates.

23.04.2026

Cartesian Therapeutics: A Phase 3 mRNA CAR-T Bet

Cartesian Therapeutics receives a buy rating, driven by a differentiated mRNA CAR-T approach for autoimmune diseases and strong insider/institutional support. RNAC's lead asset, Descartes-08, demonstrated a 7.1-point MG-ADL reduction at 12 months in Phase 2b, surpassing current biologics in durability and efficacy. The ongoing Phase 3 AURORA trial, with FDA SPA agreement and 100 patients, is a pivotal binary catalyst; $126.9M cash runway extends into mid-2027.

20.04.2026

Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?

Cartesian Therapeutics, Inc. (RNAC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

14.04.2026

Cartesian Therapeutics, Inc. (RNAC) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

02.04.2026

Cartesian Therapeutics Announces New Employment Inducement Grants

FREDERICK, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On April 1, 2026, the Company issued to these employees options to purchase an aggregate of 52,450 shares of the Company's common stock with an exercise price of $6.39, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The options vest as to 25% on April 1, 2027, and then in thirty-six substantially equal monthly installments thereafter such that the options will be fully vested on April 1, 2030. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company.

Videolar

No Data

There is no data to display

Press-relizlar

04.05.2026

Cartesian Therapeutics Announces New Employment Inducement Grants

30.04.2026

Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

02.04.2026

Cartesian Therapeutics Announces New Employment Inducement Grants

03.02.2026

Cartesian Therapeutics Announces New Employment Inducement Grants

FREDERICK, Md., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On February 2, 2026, the Company issued to these employees options to purchase an aggregate of 12,050 shares of the Company's common stock with an exercise price of $6.79, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The options vest as to 25% on February 2, 2027, and then in thirty-six substantially equal monthly installments thereafter such that the options will be fully vested on February 2, 2030. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company.

Cartesian Therapeutics, Inc. (RNAC)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Cartesian Therapeutics, Inc. (RNAC)

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates

Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Cartesian Therapeutics: A Phase 3 mRNA CAR-T Bet

Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?

Cartesian Therapeutics, Inc. (RNAC) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Cartesian Therapeutics Announces New Employment Inducement Grants

Videolar

No Data

Press-relizlar

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates

Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Cartesian Therapeutics: A Phase 3 mRNA CAR-T Bet

Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?

Cartesian Therapeutics, Inc. (RNAC) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Cartesian Therapeutics Announces New Employment Inducement Grants

Videolar

No Data

Press-relizlar

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Announces New Employment Inducement Grants

Search stocks

Cartesian Therapeutics, Inc. (RNAC)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Cartesian Therapeutics, Inc. (RNAC)

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates

Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Cartesian Therapeutics: A Phase 3 mRNA CAR-T Bet

Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?

Cartesian Therapeutics, Inc. (RNAC) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Cartesian Therapeutics Announces New Employment Inducement Grants

Videolar

No Data

Press-relizlar

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates

Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Cartesian Therapeutics: A Phase 3 mRNA CAR-T Bet

Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?

Cartesian Therapeutics, Inc. (RNAC) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Cartesian Therapeutics Announces New Employment Inducement Grants

Videolar

No Data

Press-relizlar

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Announces New Employment Inducement Grants